Fox Chase Cancer Center | Strategic Alliance Partners

July 05, 2016

Thomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.

June 29, 2016

Ranee Mehra, MD, discusses what the KEYNOTE-012 findings could mean for patients, the growing role for the immunotherapy agent in head and neck cancer, and what else is on the horizon for the treatment landscape.

June 10, 2016

Hossein Borghaei, DO, discusses the significance of the 2-year follow-up results of the CheckMate-057 and -017 studies, the evolving role of PD-L1 as a biomarker and others that are in development, and emerging immunotherapy agents in the field of non-small cell lung cancer.

April 02, 2016

Alexander Kutikov, MD, discusses the evolving role of surgery in kidney cancer.

December 21, 2015

Compelling evidence has been presented about the various checkpoint inhibitors in bladder cancer, but, additionally there have been some provocative papers looking at genomic sequencing of upper tract compared with bladder that shows certain differences

October 20, 2015

Medical oncologist Lori J. Goldstein, MD, from Fox Chase Cancer Center, have been looking at reparixin, an investigational study drug that targets breast cancer stem cells.

August 20, 2015

Fox Chase Cancer Center's breast cancer program has earned full accreditation for the third time from The National Accreditation Program for Breast Centers.

July 02, 2015

Michael J. Hall, MD, MS, director, Gastrointestinal Risk Assessment, assistant professor, Fox Chase Cancer Center, discusses multigene target panels that examine tumors for genetic weaknesses.

April 29, 2015

Although patients with invasive lobular carcinoma are typically treated with the same therapeutic strategies as those with infiltrating ductal malignancies, ILC is emerging as a molecularly complex and distinct tumor type that suggests different approaches may be effective.

February 05, 2015

Jennifer Yuchen Shih, MD, a medical oncologist at Fox Chase Cancer Center, discusses the ABCSG-8 and BIG 1-98 studies and their impacts on the treatment of lobular breast cancer compared to ductal breast cancers.

February 04, 2015

Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.

January 07, 2015

Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.

August 28, 2014

Although advances in endocrine therapy for women with estrogen receptor (ER)-positive breast cancer have been made in recent years, de novo and acquired resistance to treatments remain important clinical problems, and efforts to identify effective modalities to overcome this challenge continue.

July 16, 2014

Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses a study presented at the 2014 ASCO Annual Meeting where researchers profiled more than 1900 sarcoma specimens to try to identify potential novel treatment modalities for patients with this disease.

March 11, 2014

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial that looked at overcoming mTOR resistance with an HDAC inhibitor in renal cell carcinoma (RCC).

January 03, 2014

Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer.

November 01, 2013

Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the toxicity profile of bevacizumab when used to treat patients with ovarian cancer.

October 25, 2013

At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Michael Millenson, MD, Fox Chase Cancer Center, discussed considerations in selecting second- and third-generation tyrosine-kinase inhibitors for the management of chronic myelogenous leukemia

October 09, 2013

Robert A. Burger, MD, FACOG, FACS, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the use of bevacizumab in patients with ovarian cancer.

December 05, 2011

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes